Close

Amarin Corp. (AMRN) Tops Q4 EPS by 4c, Revs Beat; Reaffirms

Go back to Amarin Corp. (AMRN) Tops Q4 EPS by 4c, Revs Beat; Reaffirms

Amarin Reports Record Fourth Quarter and Full Year 2019 Financial Results and Provides Update on Operations

February 25, 2020 4:06 PM EST

Record Revenue of $429.8 Million and $143.3 Million for Full Year and Fourth Quarter 2019  

Launch Commenced of VASCEPA® as First and Only Drug with Its New Cardiovascular Risk Reduction Indication

Management to Host Conference Call at 4:30 p.m. ET Today

DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), today announced financial results for the quarter and year ended December 31, 2019 and provided an update on company operations.

Key Amarin recent achievements... More